Emerald Advisers LLC Has $7.34 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Emerald Advisers LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,429 shares of the biopharmaceutical company’s stock after selling 13,606 shares during the quarter. Emerald Advisers LLC’s holdings in Celldex Therapeutics were worth $7,344,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the first quarter valued at approximately $147,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 955 shares during the last quarter. Aigen Investment Management LP bought a new stake in Celldex Therapeutics in the fourth quarter worth $251,000. Ameritas Investment Partners Inc. increased its position in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 1,582 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 638 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Wells Fargo & Company upped their price target on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Stifel Nicolaus assumed coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Tuesday, July 30th. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $63.83.

Celldex Therapeutics Stock Up 0.7 %

Shares of CLDX stock opened at $43.76 on Friday. Celldex Therapeutics, Inc. has a 12 month low of $22.11 and a 12 month high of $53.18. The firm has a market cap of $2.90 billion, a PE ratio of -15.35 and a beta of 1.56. The stock has a 50 day moving average of $37.57 and a 200-day moving average of $38.96.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. As a group, equities analysts predict that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

Insider Activity

In related news, CFO Samuel Bates Martin sold 17,172 shares of Celldex Therapeutics stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $35.42, for a total transaction of $608,232.24. Following the sale, the chief financial officer now directly owns 28,125 shares of the company’s stock, valued at $996,187.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, VP Elizabeth Crowley sold 30,000 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $34.87, for a total value of $1,046,100.00. Following the completion of the transaction, the vice president now owns 9,074 shares in the company, valued at approximately $316,410.38. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Samuel Bates Martin sold 17,172 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $35.42, for a total transaction of $608,232.24. Following the transaction, the chief financial officer now directly owns 28,125 shares of the company’s stock, valued at $996,187.50. The disclosure for this sale can be found here. 3.80% of the stock is owned by company insiders.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.